Search

EP-4740961-A2 - CANNABINOID PRODUCT FOR IMPROVING MUSCULOSKELETAL HEALTH

EP4740961A2EP 4740961 A2EP4740961 A2EP 4740961A2EP-4740961-A2

Abstract

The present disclosure is directed to a composition or nutritional product containing a cannabinoid in combination with an adjuvant, such as a Type II collagen. The different nutraceutical agents are capable of synergistically working together to improve the health and well-being of a human or animal. For instance, the nutritional product can be used in many different applications, such as to treat joint discomfort and pain, and/or to improve muscular health.

Inventors

  • The designation of the inventor has not yet been filed

Assignees

  • Lonza Greenwood LLC

Dates

Publication Date
20260513
Application Date
20200930

Claims (15)

  1. A nutritional product comprising: a Type II collagen source; and a collagen adjuvant, the collagen adjuvant comprising a cannabinoid.
  2. A nutritional product as defined in claim 1, further comprising an antioxidant.
  3. A nutritional product as defined in claim 1, wherein the Type II collagen source and the collagen adjuvant have been blended together.
  4. A nutritional product as defined in any of claims 1-2, wherein the Type II collagen source and the collagen adjuvant are not blended together but are instead provided as separate entities.
  5. A nutritional product as defined in any of claims 1-4, wherein the product comprises a nutritional supplement for taking orally, and/or wherein the nutritional product comprises a food product or a beverage, such as a pet food, and/or wherein the nutritional product comprises tablets, capsules, gummy chewables, edible films, liquid suspensions, powders, syrups, lozenges, beadlets, nanoparticles, micellular emulsions, or spray-dried dispersions.
  6. A nutritional product as defined in any of claims 1-5, wherein the Type II collagen source comprises an undenatured, denatured, or hydrolyzed Type II collagen or bioactive peptide derived from Type II collagen.
  7. A nutritional product as defined in any of claims 1-6, wherein the cannabinoid comprises a cannabidiol, cannabigerol, or combinations thereof, or wherein the cannabinoid comprises cannabichromene, cannabinol, cannabigerol, tetrahydrocannabivarin, cannabidivarin, cannabidiolic acid, or mixtures thereof.
  8. A method of maintaining, improving or modulating musculoskeletal health in a mammal comprising administering to the mammal a collagen source in conjunction with a cannabinoid.
  9. A method as defined in claim 8, wherein the collagen source is a Type II collagen source, preferably wherein the Type II collagen source and the cannabinoid are combined together and administered to the mammal, or wherein the Type II collagen source and the cannabinoid are administered separately to the mammal.
  10. A method as defined in claim 8, wherein the Type II collagen source and the cannabinoid are orally administered to the mammal and/or wherein the Type II collagen source and the cannabinoid are combined with a food composition and administered to the mammal.
  11. A method as defined in any of claims 8-10, wherein the cannabinoid comprises cannabidiol and/or its components, or wherein the cannabinoid comprises cannabigerol, or wherein the cannabinoid comprises cannabichromene, cannabinol, tetrahydrocannabivarin, cannabidivarin, cannabidiolic acid, and mixtures thereof.
  12. A method as defined in any of claims 8-11, wherein the mammal is a canine, feline, equine, or bovine.
  13. A method as defined in claim 10, wherein the food composition is a pet food, or wherein the food composition is intended for human consumption.
  14. A method as defined in any of claims 8-13, wherein the Type II collagen source in conjunction with the cannabinoid are administered to the mammal in amounts and ratios sufficient to modulate cytokine production or other immunoregulatory functions in a mammal, preferably wherein the cannabinoid is cannabidiol, cannabigerol, or combinations thereof, or wherein the Type II collagen source in conjunction with the cannabinoid are administered to the mammal in amounts and ratios sufficient to modulate collagen production and/or joint repair in a mammal, or wherein the Type II collagen source in conjunction with the cannabinoid are administered to the mammal in amounts and ratios sufficient to reduce pain or the perception of pain in the mammal.
  15. A method of improving recovery time after strenuous physical activity in a mammal comprising administering to the mammal a Type II collagen source in conjunction with a cannabinoid.

Description

Related Applications The present application is based on and claims priority to U.S. Provisional Patent application Serial No. 62/908,141, filed on September 30, 2019, which is incorporated herein by reference. BACKGROUND Cannabis, or the cannabis plant, may refer to both marijuana, which is generally used for recreational purposes, and hemp, which is generally used in industrial applications. Cannabis is a green and/or brown mixture of dried, shredded leaves, stems, stalks, seeds and flowers of the plant, and may reference leaves, stems, seeds, and flowers from a Cannabis plant, varieties of which include Cannabis sativa or Cannabis indica. Hemp (and particularly the industrial hemp variety), have a very similar appearance to marijuana, but unlike the cannabis plant variety referred to by marijuana, hemp generally only contains low amounts of tetrahydrocannabinol (THC), whereas both hemp and marijuana can include high amounts of cannabidiol (CBD). For instance, hemp, and particularly industrial hemp may contain less than about 0.3% THC whereas the cannabis variety referred to by marijuana may contain anywhere from 5% to 30% THC. Recently, over 25 states in the United States have legalized the use of cannabis for at least medical purposes. In addition, Canada has now legalized the use of cannabis for medical and recreational use. In view of these recent developments, the commercialization of cannabis has dramatically increased. Cannabis, for instance, is becoming a more and more popular drug for pain relief in lieu of conventional pain relief medicines, such as opioids. Opioids are powerful pain relief medications that relieve pain by acting on the nervous system. They are typically used to treat severe pain after surgery and are also used to treat chronic pain, such as joint pain. Unfortunately, however, opioids come with many risks. For example, opioids are highly addictive which has led to an epidemic of drug misuse. In view of the above drawbacks, more and more people in the medical community have begun to view cannabis as a legitimate alternative to the use of opioids for pain relief. For instance, THC acts on specific receptors in the brain which lead to a feeling of euphoria and a relaxed state. The highest concentrations of THC in cannabis are found in the dried flowers or buds. Cannabis is typically regulated based upon the amount of THC found in the material. Although CBD does interact with pain receptors in the brain, CBD does not create the same euphoric feeling caused by THC. CBD, however, exerts pain-relieving and anti-inflammatory effects. Cannabis, and especially CBD, do not have the same addictive effect as many opioids. CBD can be administered in a variety of forms. For example, it can be delivered in the form of an oil, a powder, or as nanoparticles, which are more quickly absorbed by the body. Due to the potential of cannabis to be used as a therapeutic substance with low risk for addiction, there is a need to maximize the benefits of cannabis and extend its use into new applications. SUMMARY The present disclosure concerns a composition or nutritional product that includes a cannabinoid administered to a mammal, a patient, or a healthy individual to promote or improve musculoskeletal health. The composition further comprises a collagen source, such as a Type II collagen source. It is believed that the cannabinoid of the present disclosure not only provides pain relief but can also synergistically work in conjunction with the collagen source for promoting or modulating the health of the mammal, such as joint health. The collagen source incorporated into the nutritional product of the present disclosure can vary. For instance, it may be a Type II collagen source comprising undenatured, denatured, or hydrolyzed Type II collagen. In an alternative embodiment, the collagen source can be a bioactive peptide derived from Type II collagen. The nutritional product of the present disclosure can be used to treat all different types of musculoskeletal ailments in mammals, which are due to a disease, age (including arthritis), or various normal strenuous activities (e.g., running, walking, stair climbing, exercising, etc.), in animals or humans. The method includes administering to the mammal a therapeutically effective amount of a cannabinoid in combination with a collagen source. The compositions or products, which can be in the form of oral dosage vessels, can be administered to the mammal in an amount sufficient to reduce joint discomfort or pain, or to begin and support the healing process, or any combination thereof. Additionally, the compositions and products can be used to maintain musculoskeletal health such as healthy bones and joints for mammals of any age. Further, the compositions and products can be used as a prenatal and/or multivitamin/mineral supplement. The cannabinoid may be any known cannabinoid. In one embodiment, the cannabinoid is selected from the group consisting of cannabid